Hormones and Mood: How Estrogen and Progesterone Affect Women's Mental Health

Published by the clinical team at Roth Family Medicine and Mental Health | www.rothfamilymed.com

If you've ever felt like a different person in the week before your period — irritable, weepy, anxious, or simply unable to cope with things that normally wouldn't faze you — you've experienced firsthand what hormones can do to the brain. For many women, that monthly fluctuation is manageable. But for a significant number of women in Pocatello and throughout Southeast Idaho, the connection between hormones and mental health is far more profound and far more disruptive than anyone ever explained to them.

This article is for women who suspect their mental health struggles may have a hormonal dimension — those who feel like their depression or anxiety has a cyclical quality, or those navigating the emotional turbulence of perimenopause and menopause and wondering why their mental health has shifted so dramatically.

Understanding the hormone-mood connection isn't just interesting science. It's often the key to finally getting better.

Estrogen and progesterone are not simply reproductive hormones. They are neuroactive steroids with profound effects on brain chemistry, architecture, and function.

Estrogen:

• Increases serotonin synthesis and the density of serotonin receptors
• Enhances dopamine transmission in areas involved in reward and motivation
• Supports BDNF (brain-derived neurotrophic factor), which promotes neuroplasticity and resilience
• Has anti-inflammatory effects in the brain
• Modulates the stress response via the HPA axis

Progesterone:

• Converts to allopregnanolone, a potent positive modulator of GABA receptors — essentially a natural anxiolytic
• Has a calming, sedating effect at stable levels
• But produces mood-disrupting effects when levels fluctuate rapidly, which is what happens in the late luteal phase of the menstrual cycle and during perimenopause

This neuroactive profile explains why hormonal fluctuations can produce symptoms that are clinically indistinguishable from depression, anxiety, and mood instability — because they're affecting the same neurochemical systems that psychiatric medications target.

Premenstrual Syndrome (PMS) is common. Premenstrual Dysphoric Disorder (PMDD) is a different animal.

PMDD is a DSM-5 recognized mood disorder characterized by severe emotional and psychological symptoms that reliably appear in the late luteal phase (typically the 1–2 weeks before menstruation) and resolve within days of menstrual onset. It affects approximately 3–8% of women of reproductive age.

Symptoms include:

• Marked affective lability (sudden tearfulness, sensitivity to rejection)
• Irritability or anger, often out of proportion to circumstances
• Depressed mood, hopelessness, or self-critical thoughts
• Marked anxiety or tension
• Decreased interest in activities (anhedonia)
• Difficulty concentrating
• Fatigue
• Physical symptoms: breast tenderness, bloating, joint/muscle pain

The critical diagnostic feature is cyclicity — symptoms are time-locked to the luteal phase and clear (fully or substantially) after menstruation.

PMDD requires treatment. SSRIs (particularly sertraline and fluoxetine) can be used continuously or luteal-phase only with good evidence. Hormonal interventions — combined oral contraceptives or GnRH agonists in severe cases — address the underlying hormonal trigger.

Perimenopause — the transitional period leading up to menopause, typically beginning in the mid-to-late 40s — is one of the most significant and underrecognized risk periods for women's mental health.

The data is striking:

• Women are two to four times more likely to experience a major depressive episode during perimenopause than during their premenopausal years
• Anxiety symptoms increase significantly in the menopausal transition
• For women who previously had depression, the perimenopause period is a time of substantially elevated risk of recurrence

Why? Because perimenopause is characterized by erratic, unpredictable estrogen fluctuations — not just a gradual decline, but a rollercoaster of highs and lows that destabilize the serotonin and GABA systems that estrogen normally helps regulate.

Common mental health symptoms of perimenopause include:

• New-onset depression, even in women with no psychiatric history
• Anxiety and panic attacks
• Cognitive changes — "brain fog," word-finding difficulty, memory lapses
• Irritability and emotional lability
• Sleep disruption (often driven by night sweats and hot flashes, which then compound mood disturbance)
• Loss of motivation and sense of self

Many women in this phase are prescribed antidepressants by providers who don't recognize the hormonal component. SSRIs can be helpful, but they don't address the underlying hormonal dysregulation — and for some women, the addition of appropriate hormone therapy is transformative in a way that antidepressants alone cannot be.

Menopausal hormone therapy (MHT) — formerly called HRT — has been subject to decades of controversy following the 2002 Women's Health Initiative study, which raised concerns about breast cancer and cardiovascular risk. Subsequent research has substantially refined the risk picture, and the current clinical consensus is nuanced:

• For women under 60 or within 10 years of menopause onset, the benefits of MHT generally outweigh the risks for most women without contraindications
• Modern transdermal estrogen (patch, gel, or spray) does not carry the thrombotic risk associated with oral estradiol
• Micronized progesterone (Prometrium) has a more favorable safety profile than synthetic progestins
• The breast cancer risk increase with combined MHT is small in absolute terms and varies significantly with the formulation used

For women experiencing perimenopausal depression or mood instability, evidence suggests that transdermal estradiol has antidepressant effects that go beyond simply relieving hot flashes and sleep disruption — it appears to directly stabilize the serotonergic and dopaminergic systems that fluctuating estrogen has destabilized.

Beyond estrogen and progesterone, several other physiological factors frequently compound hormonal mental health challenges in women:

• Thyroid dysfunction: Hypothyroidism is far more common in women than men and produces symptoms virtually identical to depression. Thyroid disorders also worsen during the perimenopausal transition.
• Testosterone: Often overlooked in women, low testosterone is associated with low libido, fatigue, flat mood, and reduced motivation.
• Cortisol dysregulation: Chronic stress elevates cortisol, which disrupts estrogen-progesterone balance and compounds mood disturbance.
• Nutrient status: Iron deficiency, B12, folate, and vitamin D deficiencies are common in women and exacerbate mood and energy symptoms.
• Gut microbiome: The gut microbiome plays a role in estrogen metabolism via the "estrobolome" — gut bacteria that regulate estrogen recycling.

Consider a comprehensive hormone and mental health evaluation if you are a woman experiencing:

• Depression or anxiety with a cyclical pattern
• New or worsening mood symptoms in your 40s or early 50s
• Mood symptoms accompanied by hot flashes, night sweats, sleep disruption, or changes in menstrual cycle
• Depression that hasn't adequately responded to antidepressants
• Cognitive changes — "brain fog," memory lapses — alongside mood symptoms
• Loss of libido alongside depression or low motivation

Can hormones really cause clinical depression? Yes. Hormonal fluctuations — particularly in estrogen and progesterone — directly affect the neurotransmitter systems involved in mood. Perimenopausal depression is a biologically distinct phenomenon from depression at other life stages, and treating it effectively often requires addressing the hormonal component.

Are antidepressants the wrong choice for hormonal depression? Not necessarily. SSRIs and SNRIs can be appropriate, particularly when depression is moderate-to-severe. But for perimenopausal depression driven primarily by estrogen dysregulation, hormone therapy may be more targeted and effective — either alone or in combination.

What lab tests should I get? A reasonable starting panel includes: FSH, LH, estradiol, progesterone (timed to cycle phase), testosterone (free and total), DHEA-S, thyroid panel (TSH, free T3, free T4, thyroid antibodies), cortisol (ideally 4-point salivary), CBC, ferritin, B12, folate, and vitamin D.

For women, the separation between "hormone issues" and "mental health issues" is often a false one. The brain runs on hormones, and when hormones fluctuate — monthly, across the lifespan, or in response to chronic stress — the brain feels it.

At Roth Family Medicine and Mental Health, we evaluate women's mental health through an integrated lens that includes hormones, thyroid function, adrenal status, and nutritional factors — not just a DSM checklist. We serve women in Pocatello, Chubbuck, Blackfoot, and throughout Southeast Idaho.

Medical Disclaimer: This article is intended for educational purposes only and does not constitute medical advice. Always consult a licensed medical professional before starting, changing, or stopping any treatment. Hormone therapy carries risks and benefits that must be discussed with a qualified provider in the context of your individual health history.

Kyle Roth, FNP-BC, APRN, MSN, MHA | Roth Family Medicine and Mental Health | Pocatello, Idaho | 208-904-4705 | www.rothfamilymed.com